We have discovered a novel compound, NO-1886, which possesses a powerful lipoprotein lipase (LPL) activity-increasing action. Administration of NO-1886 increased LPL activity in the postheparin plasma, adipose tissue, and myocardium of rats, and produced a reduction in plasma triglyceride levels with concomitant elevation of HDL cholesterol levels. Administration of NO-1886 increased LPL enzyme mass in postheparin plasma and mRNA activity in epididymal adipose tissue, and it was concluded that the mode of action of this compound is stimulation of tissue LPL synthesis. We also conducted long-term studies to assess the impact of increases in LPL activity and HDL levels on the development of atherosclerotic lesions in rats. Administration of NO-1886 for as long as 90 d significantly decreased the degree of atherosclerotic changes in the coronary arteries of vitamin D2-treated, cholesterol-fed rats. Statistical analysis indicated that increased concentration of HDL is the factor contributing mostly to the prevention of coronary artery sclerosis. In summary, the results of our study indicate that compound NO-1886 increases LPL activity, causing an elevation in HDL levels, and that long-term administration of NO-1886 to rats with experimental atherosclerosis provides significant protection against the development of coronary artery lesions.
K Tsutsumi, Y Inoue, A Shima, K Iwasaki, M Kawamura, T Murase
Title and authors | Publication | Year |
---|---|---|
Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats
M Kusunoki, K Tsutsumi, D Sato, A Nakamura, S Habu, Y Mori, M Morishita, T Yonemoto, T Miyata, Y Nakaya, T Nakamura |
European Journal of Pharmacology | 2011 |
Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs
Y Liu, ZB Wang, WD Yin, QK Li, MB Cai, J Yu, HG Li, C Zhang, XH Zu |
Lipids in Health and Disease | 2011 |
Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886
M Kusunoki, K Tsutsumi, D Sato, A Nakamura, S Habu, Y Mori, M Morishita, T Yonemoto, T Miyata, Y Nakaya, T Nakamura |
European Journal of Pharmacology | 2011 |
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee |
Annual Reports in Medicinal Chemistry Volume 46 | 2011 |
Lipoprotein Lipase as a Candidate Target for Cancer Prevention/Therapy
S Takasu, M Mutoh, M Takahashi, H Nakagama |
Biochemistry Research International | 2011 |
NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signalling : NO-1886 ameliorated the insulin resistance
Z Wang, H Zeng, H Wei, G Yi, J Yu, Y Wang, Y Zhang, W Yin |
Journal of Pharmacy and Pharmacology | 2011 |